688443 Chongqing Genrix Biopharmaceutical
- 29.37
- -0.86-2.84%
Chongqing Genrix Biopharmaceutical News
Announcement on holding the results briefing for the third quarter of 2024
Zhixiang Jintai: Announcement of Resolutions of the 16th Meeting of the First Board of Directors
Announcement of Resolutions of the 16th Meeting of the First Board of Directors
Zhixiang Jintai Investor Relations Activity Record Form (2024 Semi-Annual Results Briefing)
Inspection opinions of Haitong Securities Co., Ltd. on the initial public offering of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. and the listing circulation of some restricted shares
Announcement on holding the 2024 semi-annual results briefing
Haitong Securities Co., Ltd.\'s 2024 continuous supervision semi-annual follow-up report on Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.
Announcement of Resolutions of the 15th Meeting of the First Board of Directors
Special Report on the Deposit and Actual Use of Funds Raised for the Semiannual Year of 2024
Announcement of Resolutions of the 14th Meeting of the First Board of Supervisors
Voluntary disclosure of the announcement on the approval of the drug clinical trial approval notice for the indication of GR1802 injection for children and adolescents with atopic dermatitis.
Verification opinion on the regulatory inquiry letter regarding the information disclosure of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.'s 2023 annual report by Haitong Securities Co., Ltd.
Special General Partnership of ShineWing Certified Public Accountants LLP's specific explanation on the regulatory inquiry letter regarding information disclosure related to Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.'s 2023 annual report.
Zhixiang Jintai Investor Relations Activity Record Form (2023 Science and Technology Innovation Board Biological Products (2) Group Performance Briefing)
Shanghai AllBright Law Firm's special inspection opinion on the increase in shares held by the actual controller of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.
Announcement on attending the 2023 Science and Technology Innovation Board Biological Products (2) Group Performance Briefing
Evaluation report on the performance of accounting firms in 2023
2023 Independent Director Debriefing Report-Hu Yuntong
2023 Independent Director Debriefing Report-Wei Dongzhi
Haitong Securities Co., Ltd.'s 2023 Continuous Supervision Annual Follow-up Report on Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.
Analysis
Price Target
No Data
No Data